Chimeric antibodies with the antigen‐binding region kept xenogenic, targeting self‐antigens are presently used successfully to treat cancer (anti‐CD20/rituximab), graft‐versus‐host disease (anti‐CD25/basiliximab), and various autoimmune diseases (anti‐TNF [tumor necrosis factor]/infliximab). Here, TNF is linked to autoimmune disease.